Precision Medicine Offers Belatacept Monotherapy

Summary

The purpose of this study is to determine the safety and feasibility of converting patients to Belatacept monotherapy (receiving just one immunosuppression drug), and to see what percentage of those patients can be safely converted to once every 8 week administration of Belatacept. Belatacept has been approved by the Food and Drug Administration (FDA) for kidney transplant recipients.

Timeline

Start

2019-02

Primary completion

2020-02

Completion

2022-12

Outcome

Outcome not reported

Stopped: “Because of inability to get FDA approval for”

Drugs

Indications